Skip to main content
Top
Published in: Osteoporosis International 12/2017

01-12-2017 | Short Communication

Self-perception of fracture risk: what can it tell us?

Authors: A. E. Litwic, J. E. Compston, A. Wyman, E. S. Siris, S. H. Gehlbach, J. D. Adachi, R. Chapurlat, A. Díez-Pérez, A. Z. LaCroix, J. W. Nieves, J. C. Netelenbos, J. Pfeilschifter, M. Rossini, C. Roux, K. G. Saag, S. Silverman, N. B. Watts, S. L. Greenspan, L. March, C. L. Gregson, C. Cooper, E. M. Dennison, Global Longitudinal Study of Osteoporosis in Women (GLOW) Investigators

Published in: Osteoporosis International | Issue 12/2017

Login to get access

Abstract

Summary

In this study, we report that self-perception of fracture risk captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is associated with improved medication uptake. It suggests that adequate appreciation of fracture risk may be beneficial and lead to greater healthcare engagement and treatment.

Introduction

This study aimed to assess how well self-perception of fracture risk, and fracture risk as estimated by the fracture prediction tool FRAX, related to fracture incidence and uptake and persistence of anti-osteoporosis medication among women participating in the Global Longitudinal study of Osteoporosis in Women (GLOW).

Methods

GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America and Australia. Aged ≥ 55 years, 60,393 women completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk (SPR). Annual follow-up included self-reported incident fractures and anti-osteoporosis medication (AOM) use. We calculated FRAX risk without bone mineral density measurement.

Results

Of the 39,241 women with at least 1 year of follow-up data, 2132 (5.4%) sustained an incident major osteoporotic fracture over 5 years of follow-up. Within each SPR category, risk of fracture increased as the FRAX categorisation of risk increased. In GLOW, only 11% of women with a lower baseline SPR were taking AOM at baseline, compared with 46% of women with a higher SPR. AOM use tended to increase in the years after a reported fracture. However, women with a lower SPR who were fractured still reported lower AOM rates than women with or without a fracture but had a higher SPR.

Conclusions

These results suggest that SPR captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is also associated with improved medication uptake.
Literature
1.
go back to reference van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517–522CrossRefPubMed van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517–522CrossRefPubMed
2.
go back to reference Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res: Off J Am Soc Bone Miner Res 22:465–475CrossRef Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res: Off J Am Soc Bone Miner Res 22:465–475CrossRef
3.
go back to reference Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentral Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentral
4.
go back to reference Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652CrossRefPubMed Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652CrossRefPubMed
5.
go back to reference Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL (2008) Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 3:371–384CrossRefPubMedPubMedCentral Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL (2008) Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 3:371–384CrossRefPubMedPubMedCentral
6.
go back to reference Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155:772–779CrossRefPubMed Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155:772–779CrossRefPubMed
7.
go back to reference Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM (2000) Adherence in chronic disease. Annu Rev Nurs Res 18:48–90PubMed Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM (2000) Adherence in chronic disease. Annu Rev Nurs Res 18:48–90PubMed
8.
go back to reference Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMed Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMed
9.
go back to reference Cline RR, Farley JF, Hansen RA, Schommer JC (2005) Osteoporosis beliefs and antiresorptive medication use. Maturitas 50:196–208CrossRefPubMed Cline RR, Farley JF, Hansen RA, Schommer JC (2005) Osteoporosis beliefs and antiresorptive medication use. Maturitas 50:196–208CrossRefPubMed
10.
go back to reference Siris ES, Gehlbach S, Adachi JD et al (2011) Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 22:27–35CrossRefPubMed Siris ES, Gehlbach S, Adachi JD et al (2011) Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 22:27–35CrossRefPubMed
11.
go back to reference Hooven FH, Adachi JD, Adami S et al (2009) The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int 20:1107–1116CrossRefPubMedPubMedCentral Hooven FH, Adachi JD, Adami S et al (2009) The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int 20:1107–1116CrossRefPubMedPubMedCentral
12.
go back to reference Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX((R)) with and without bone mineral density. Calcif Tissue Int 90:1–13CrossRefPubMed Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX((R)) with and without bone mineral density. Calcif Tissue Int 90:1–13CrossRefPubMed
13.
go back to reference Rothmann MJ, Ammentorp J, Bech M, Gram J, Rasmussen OW, Barkmann R, Gluer CC, Hermann AP (2015) Self-perceived facture risk: factors underlying women’s perception of risk for osteoporotic fractures: the \aluation study (ROSE). Osteoporos Int 26:689–697CrossRefPubMed Rothmann MJ, Ammentorp J, Bech M, Gram J, Rasmussen OW, Barkmann R, Gluer CC, Hermann AP (2015) Self-perceived facture risk: factors underlying women’s perception of risk for osteoporotic fractures: the \aluation study (ROSE). Osteoporos Int 26:689–697CrossRefPubMed
14.
go back to reference Gregson CL, Dennison EM, Compston JE et al (2014) Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int 25:85–95CrossRefPubMed Gregson CL, Dennison EM, Compston JE et al (2014) Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int 25:85–95CrossRefPubMed
15.
go back to reference Hadjistavropoulos T, Delbaere K, Fitzgerald TD (2011) Reconceptualizing the role of fear of falling and balance confidence in fall risk. J Aging Health 23:3–23CrossRefPubMed Hadjistavropoulos T, Delbaere K, Fitzgerald TD (2011) Reconceptualizing the role of fear of falling and balance confidence in fall risk. J Aging Health 23:3–23CrossRefPubMed
16.
go back to reference Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960CrossRefPubMed Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960CrossRefPubMed
17.
go back to reference Greenspan SL, Wyman A, Hooven FH et al (2012) Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc 60:455–461CrossRefPubMedPubMedCentral Greenspan SL, Wyman A, Hooven FH et al (2012) Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc 60:455–461CrossRefPubMedPubMedCentral
18.
go back to reference Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23:1815–1821CrossRefPubMedPubMedCentral Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23:1815–1821CrossRefPubMedPubMedCentral
19.
go back to reference Gehlbach S, Hooven FH, Wyman A, Diez-Perez A, Adachi JD, Luo X, Bushmakin AG, Anderson FA (2013) Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS One 8:e82840CrossRefPubMedPubMedCentral Gehlbach S, Hooven FH, Wyman A, Diez-Perez A, Adachi JD, Luo X, Bushmakin AG, Anderson FA (2013) Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS One 8:e82840CrossRefPubMedPubMedCentral
20.
go back to reference Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG (2006) Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf 15:710–718CrossRefPubMed Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG (2006) Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf 15:710–718CrossRefPubMed
Metadata
Title
Self-perception of fracture risk: what can it tell us?
Authors
A. E. Litwic
J. E. Compston
A. Wyman
E. S. Siris
S. H. Gehlbach
J. D. Adachi
R. Chapurlat
A. Díez-Pérez
A. Z. LaCroix
J. W. Nieves
J. C. Netelenbos
J. Pfeilschifter
M. Rossini
C. Roux
K. G. Saag
S. Silverman
N. B. Watts
S. L. Greenspan
L. March
C. L. Gregson
C. Cooper
E. M. Dennison
Global Longitudinal Study of Osteoporosis in Women (GLOW) Investigators
Publication date
01-12-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4200-3

Other articles of this Issue 12/2017

Osteoporosis International 12/2017 Go to the issue